BMY Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$52.49
Updated
Bristol-Myers Squibb Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.85 |
| 52 Week High | US$69.10 |
| 52 Week Low | US$44.34 |
| Beta | 0.39 |
| 1 Month Change | -15.77% |
| 3 Month Change | -9.76% |
| 1 Year Change | -32.83% |
| 3 Year Change | -28.15% |
| 5 Year Change | -7.75% |
| Change since IPO | 1,999.01% |
Recent News & Updates
Is Bristol Myers Squibb A Buy At These Bottom Levels?
Apr 22Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
Apr 12Recent updates
Is Bristol Myers Squibb A Buy At These Bottom Levels?
Apr 22Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
Apr 12Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
Apr 02Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 21
Bristol-Myers Squibb Is Not A Buy For Me
Mar 19Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
Mar 07Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 07We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative
Feb 20Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Feb 06Bristol-Myers Squibb: Massive Discount Spells Opportunity
Feb 04BMY: Might Be Approaching A Bottom In 2024
Jan 23Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings
Jan 16Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also
Jan 10Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Dec 31Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60
Dec 26Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now
Dec 19Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock
Dec 12Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.60
Dec 11Bristol-Myers Squibb: The Patent Expiry Challenge
Nov 23Bristol Myers Squibb: Bright Future Ahead
Nov 17Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Nov 08Shareholder Returns
| BMY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.3% | 0.7% | 2.9% |
| 1Y | -32.8% | 10.8% | 22.2% |
Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: BMY underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| BMY volatility | |
|---|---|
| BMY Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BMY has not had significant price volatility in the past 3 months.
Volatility Over Time: BMY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 34,100 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
| BMY fundamental statistics | |
|---|---|
| Market cap | US$90.92b |
| Earnings (TTM) | -US$6.15b |
| Revenue (TTM) | US$45.53b |
2.0x
P/S Ratio-14.8x
P/E RatioIs BMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMY income statement (TTM) | |
|---|---|
| Revenue | US$45.53b |
| Cost of Revenue | US$10.92b |
| Gross Profit | US$34.62b |
| Other Expenses | US$40.77b |
| Earnings | -US$6.15b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 26, 2024
| Earnings per share (EPS) | -3.03 |
| Gross Margin | 76.03% |
| Net Profit Margin | -13.50% |
| Debt/Equity Ratio | 336.7% |
How did BMY perform over the long term?
See historical performance and comparison